Fluorodopa

Not to be confused with Florbetapir (18F).

Fluorodopa, also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).^[1]

Fluorodopa

Clinical data
Trade names	Fluorodopa F18
Other names	6-fluoro-L-DOPA, FDOPA
License data	US DailyMed: Fluorodopa
Routes of administration	Intravenous
ATC code	V09IX05 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name (2S)-2-amino-3-(2-(18F)fluoranyl-4,5-dihydroxyphenyl)propanoic acid
CAS Number	92812-82-3
PubChem CID	56494
DrugBank	DB13848
ChemSpider	50970
UNII	2C598205QX
KEGG	D04220
ChEBI	CHEBI:49166
ChEMBL	ChEMBL3400972
CompTox Dashboard (EPA)	DTXSID90226257
Chemical and physical data
Formula	C9H10FNO4
Molar mass	214.18 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N
InChI InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1 Key:PAXWQORCRCBOCU-RPDRGXCHSA-N

The most common side effects are injection site pain.^[2]

Medical uses

Fluorodopa is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes (PS).^[2]

History

In October 2019, Fluorodopa was approved in the United States for the visual detection of certain nerve cells in adult patients with suspected Parkinsonian Syndromes (PS).^[3][4]

The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS.^[3] The trial was conducted at one clinical site in the United States.^[3]